Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial
Nevalainen, Olli P.O.; Horstia, Saana; Laakkonen, Sanna; Rutanen, Jarno; Mustonen, Jussi M.J.; Kalliala, Ilkka E.J.; Ansakorpi, Hanna; Kreivi, Hanna Riikka; Kuutti, Pauliina; Paajanen, Juuso; Parkkila, Seppo; Paukkeri, Erja Leena; Perola, Markus; Pourjamal, Negar; Renner, Andreas; Rosberg, Tuomas; Rutanen, Taija; Savolainen, Joni; Haukka, Jari K.; Guyatt, Gordon H.; Tikkinen, Kari A.O. (2022-10)
10 / 2022
Nature Communications
6152
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202211018042
https://urn.fi/URN:NBN:fi:tuni-202211018042
Kuvaus
Peer reviewed
Tiivistelmä
We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.
Kokoelmat
- TUNICRIS-julkaisut [22159]